Aplastic Anemia & MDS International Foundation, Inc.
Text Size     | Printer-friendly page

Myelodysplastic Syndromes Clinical Trials

Not all trials are listed on www.ClinicalTrials.gov.  The investigators may have chosen not to register the trial, or the study may not be eligible to be listed on ClinicalTrials.gov.  If the study has not, for example, been approved by a human subject review board, it cannot be posted.  Some trials are not listed because the investigators are not planning to publish the research findings, so you can ask the study coordinator why the study has not been included on ClinicalTrials.gov before you give your consent to participate. 

The information on the studies linked below is provided strictly as a resource, not as an endorsement of any given treatment, doctor, or medical center.
 
Remember, before you sign a consent form, Clinical Trials Explained can help you understand the potential risks and benefits of a clinical trial.  You can also contact the AA&MDSIF staff to discuss any questions you have at clinicaltrials@aamds.org or by calling the office at 410.867.0242 or 800.747.2820.

Last Modified: December 20, 2007

Bone Marrow Failure Disease Consortium

Bone Marrow Failure Disease Consortium, Multiple Protocols for Aplastic Anemia, PNH, and MDS

Protocol Multiple Protocols | Multiple Sites

View Details >>

Children's Hospital of New York Presbyterian

Allogeneic Stem Cell Transplantation Followed by Targeted Immune Therapy in Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia AML/MDS/JMML

Protocol 01-504 | New York, New York

View Details >>

Dana Farber Cancer Institute

Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation from Haploidentical Donor for Patients with Myelodysplasia

Protocol DFCI# 05-030 | Boston, Massachusetts

View Details >>

Fox Chase – Temple University, BMT Program

Fludarabine and Melphalan Followed by Healthy Donor Stem Cell Transplantation for Hematologic Malignancies

Protocol 121 | Philadelphia, Pennsylvania

View Details >>

Fred Hutchinson Cancer Research Center

Radiolabeled BC8 (anti-CD-45) Antibody Combined with Cyclophosphamide and Total Body Irradiation Followed by HLA-Matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome

Protocol FHCRC #1297 | Seattle, Washington

View Details >>

M.D. Anderson Cancer Center

Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients with Newly Diagnosed Aplastic Anemia or with Hypoplastic Myelodysplastic Syndrome

Protocol MDA 2005-0115 | Houston, Texas

View Details >>

Memorial Sloan Kettering Cancer Center

A Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients with Myelodysplastic Syndromes

Protocol 06-054 | New York, New York

View Details >>

Seattle Genetics

A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid®) in Patients With Myelodysplastic Syndromes (MDS)

Protocol SG033-0002 WIRB Pr. No.: 20070491 | Multiple Locations

View Details >>

Slone Epidemiology Center

Patient Registries at Slone: Myelodysplastic Syndromes

Boston, Massachusetts and Multiple Locations

View Details >>

St. Vincent's Comprehensive Cancer Center

A Phase I, Multi-Dose Study of SGN-33 (anti-huCD33 mAb;HuM195; lintuzumab) in Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Protocol SG033-0001 | New York, New York

View Details >>


Join Us | Make A Donation | Site Map | Glossary | Legal & Privacy Notices
AA&MDSIF, PO Box 310, Churchton, MD 20733 U.S.A. help@aamds.org